ALC News and Press, Alcon Inc. From 03/07/22

Clareon family of intraocular lenses (IOLs) delivers excellent vision, exceptional clarity and predictable refractive outcomes in a glistening-free § IOL material 1-3 Long-lasting clarity of the Clareon IOL and extensive real-world experience with excellent outc...

The following slide deck was published by Alcon Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Alcon Inc. 2021 Q4 - Results - Earnings Call Presentation

Alcon Inc. (ALC) Q4 2021 Earnings Conference Call February 16, 2022 08:00 AM ET Company Participants Karen King - Senior Vice President, Head, Global Corporate Affairs & Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Pa...

Alcon (NYSE:ALC) stock is trading 5% higher in after-hours trading after the company reported Q4 2021 earnings that beat on both the bottom and top lines. The company also provided bullish revenue and earnings guidance for 2022. Diluted EPS in Q4 of $0.28 was a ~47% increase from Q4...

Alcon press release (NYSE:ALC): Q4 Non-GAAP EPS of $0.56 beats by $0.06. Revenue of $2.13B (+10.4% Y/Y) beats by $30M. FY22 Guidace: Net sales of $8.7B-$8.9B. Core EPS of $2.35-$2.45. For further details see: Alcon Non-GAAP EPS of $0.56 beats by $0.06, revenue of $2.13B beats by $30M

Fourth Quarter 2021 sales of $2.1 billion, up 11% or 13% constant currency Full Year 2021 sales of $8.2 billion, up 22% or 20% constant currency Above-market growth in both Surgical and Vision Care; sales momentum from key products, new product launches and commercia...

Alcon (NYSE:ALC) is scheduled to announce Q4 earnings results on Tuesday, Feb. 15, after market close. The consensus EPS estimate is $0.50 (+11.1% Y/Y) and the consensus revenue estimate is $2.1B (+8.8% Y/Y). Over the last 2 years, ALC has beaten EPS estimates 75% of the time and has beaten r...

BMEZ was one of the best performing funds in 2020, the year it launched as it hit the market at the right time. This success did not carry over to 2021, as it was one of the seemingly few funds to produce losses for the year. It has been an even tougher go as we enter into 2022, a...

The Cooper Companies is a solid firm that focuses on treating vision needs. Long term, the company will likely continue to expand, but that doesn't mean it makes for a good investment. At current pricing, shares just look far too pricey for investors, even as they are fairly value...

Clinically proven to relieve all types of dry eye, 1 Systane Complete is now preservative-free and available in a multi-dose bottle Joins the fast-growing, preservative-free segment of artificial tears, representing over 40% of the global category 2 A...